Hydroxychloroquine ototoxicity in a patient with rheumatoid arthritis.
We report a case of reversible sensorineural hearing loss due to hydroxychloroquine (HQ) treatment. The patient was a 34-year-old woman with 1 year of rheumatoid arthritis (RA). She developed reversible hearing loss after 5 months of HQ treatment. Sensorineural deafness has previously been reported with chloroquine treatment, but this is the first report of ototoxicity associated with HQ in RA.
Seçkin
U
U
Department of Physical Medicine and Rehabilitation, Ankara Numune Education and Research Hospital, Turkey. pinarb@ato.org.tr
Ozoran
K
K
Ikinciogullari
A
A
Borman
P
P
Bostan
E E
EE
D000328:Adult; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D003638:Deafness / Q000139:chemically induced*; D005260:Female; D006801:Humans; D006886:Hydroxychloroquine / Q000009:adverse effects* / Q000627:therapeutic use
D018501:Antirheumatic Agents; D006886:Hydroxychloroquine